Literature DB >> 21995527

Conditionally replicating adenoviruses carrying mda-7/IL-24 for cancer therapy.

Guan Jiang1, Lei Zhang, Yong Xin, Dong-Sheng Pei, Zhi-Ping Wei, Yan-Qun Liu, Jun-Nian Zheng.   

Abstract

BACKGROUND: Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) suppresses growth and induces apoptosis in a broad range of human cancers without significant cytotoxicity to normal cells. Conditionally replicating adenoviruses (CRAds) not only have the ability to destroy cancer cells but may also be potential vectors for the expression of therapeutic genes.
METHODS: This review provides an overview of specifications for a novel anti-tumor approach CRAds carrying IL-24, and discusses recent progress in this field.
RESULTS: Studies in multiple laboratories report that CRAds carrying IL-24 selectively induced apoptosis in some cancer cells, and enhanced selective toxicity to cancer cells when combined with chemotherapeutic agents.
CONCLUSION: CRAds carrying IL-24 may prove a novel and effective approach for the treatment of cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21995527     DOI: 10.3109/0284186X.2011.621447

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  IL-24 sensitizes tumor cells to TLR3-mediated apoptosis.

Authors:  R Weiss; M Sachet; J Zinngrebe; T Aschacher; M Krainer; B Hegedus; H Walczak; M Bergmann
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

2.  Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice.

Authors:  Bin He; Xiuyan Huang; Xinyuan Liu; Bin Xu
Journal:  Mol Biol Rep       Date:  2013-05-11       Impact factor: 2.316

3.  A conditionally replicating adenovirus expressing IL-24 acts synergistically with temozolomide to enhance apoptosis in melanoma cells in vitro.

Authors:  Zhen Liang; Chun-Sheng Yang; Feng Gu; Lan-Sheng Zhang
Journal:  Oncol Lett       Date:  2017-04-07       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.